Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Cellectis S.A. CLLS

Healthcare  —  Biotechnology
1.47 0.04 2.80% as of 25 Sep
Market cap
$103.4M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Cellectis S.A. (CLLS) Business Profile

Updated before January 2025

Company Overview

Cellectis S.A. (NASDAQ: CLLS) is a pioneering biotechnology company specializing in gene-editing technologies. Founded in 1999 by André Choulika, the company is headquartered in Paris, France, with additional operations in New York, USA. Cellectis is a leader in the field of genome engineering, leveraging its proprietary TALEN® (Transcription Activator-Like Effector Nucleases) technology to develop innovative solutions in the life sciences sector. The company is led by Dr. André Choulika, who serves as Chairman and CEO, and has been instrumental in steering the company toward groundbreaking advancements in gene-editing therapies. Other key members of the leadership team include Philippe Duchateau, Chief Scientific Officer, and William Monteith, Chief Operating Officer.

Core Business Segments

Cellectis operates in two primary business segments: Therapeutics and Plant Sciences.

Therapeutics

Cellectis focuses on developing allogeneic CAR-T (Chimeric Antigen Receptor T-cell) therapies for the treatment of cancer. Unlike autologous CAR-T therapies, which use a patient’s own cells, Cellectis’s allogeneic approach uses donor-derived T-cells that are genetically modified to target cancer cells. This approach offers several advantages, including reduced costs, faster treatment timelines, and scalability. Key products and programs under this segment include:

  • UCART19: A CAR-T therapy targeting CD19-positive hematological malignancies, developed in collaboration with Servier and Allogene Therapeutics.
  • UCART22: Designed for the treatment of acute lymphoblastic leukemia (ALL).
  • UCART123: Targeting acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN).
  • UCARTCS1: Focused on multiple myeloma.

Plant Sciences

Cellectis also applies its gene-editing expertise to agriculture through its subsidiary, Calyxt, Inc. This segment focuses on developing high-value crops with improved traits such as disease resistance, drought tolerance, and enhanced nutritional profiles. Products include:

  • High-oleic soybean oil
  • Disease-resistant wheat
  • Herbicide-tolerant alfalfa

Business Model

Cellectis’s business model is built on leveraging its proprietary TALEN® technology to create innovative solutions in both healthcare and agriculture. The company generates revenue through a combination of:

  1. Collaborations and Licensing Agreements: Cellectis partners with pharmaceutical companies like Servier and Allogene Therapeutics to co-develop therapies. These partnerships often include upfront payments, milestone payments, and royalties on product sales.
  2. Product Sales: Revenue from the commercialization of gene-edited crops through its Calyxt subsidiary.
  3. Research and Development Services: Offering R&D services to third parties in the life sciences sector.

Strategic Direction

Cellectis is focused on expanding its pipeline of allogeneic CAR-T therapies and advancing its clinical trials. The company aims to:

  • Expand Therapeutic Applications: Develop CAR-T therapies for a broader range of cancers and potentially other diseases.
  • Enhance Manufacturing Capabilities: Invest in state-of-the-art manufacturing facilities to scale up production and reduce costs.
  • Sustainability Goals: Through its Calyxt subsidiary, Cellectis is committed to developing sustainable agricultural solutions that address global food security challenges.
  • Explore New Markets: The company is exploring opportunities to apply its gene-editing technology to other sectors, such as industrial biotechnology.

Competitive Landscape

Cellectis operates in a highly competitive environment, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • CRISPR Therapeutics: A leader in CRISPR-Cas9 gene-editing technology.
  • Editas Medicine: Focused on developing CRISPR-based therapies.
  • Intellia Therapeutics: Another major player in the CRISPR space.
  • Bluebird Bio: Specializes in gene therapies for rare diseases and cancer.
  • Kite Pharma (a Gilead company): A leader in autologous CAR-T therapies.

In the agricultural sector, competitors include Bayer CropScience, Corteva Agriscience, and Syngenta, which are also developing gene-edited crops.

Risk Factors

Cellectis faces several risks that could impact its operations and financial performance:

  1. Regulatory Challenges: The approval process for gene-editing therapies is complex and time-consuming.
  2. Market Dependence: The company’s success is heavily reliant on the commercialization of its CAR-T therapies and gene-edited crops.
  3. Supply Chain Disruptions: Dependence on third-party suppliers for raw materials and manufacturing could pose risks.
  4. Competition: Intense competition in both the therapeutic and agricultural sectors could limit market share.
  5. Financial Risks: As a clinical-stage company, Cellectis is not yet profitable and relies on external funding.

Recent Developments

  • Clinical Trials: Cellectis has made significant progress in its clinical trials for UCART19, UCART22, and UCART123, with promising preliminary results.
  • Manufacturing Facility: The company recently inaugurated a new manufacturing facility in Raleigh, North Carolina, to support the production of its CAR-T therapies.
  • Calyxt Partnership: Calyxt announced a collaboration with a major agricultural company to co-develop gene-edited crops.
  • COVID-19 Impact: The pandemic caused delays in clinical trials and supply chain disruptions but also highlighted the importance of innovative healthcare solutions.

Investment Considerations

Strengths

  • Proprietary Technology: Cellectis’s TALEN® platform is a proven and versatile gene-editing tool.
  • Strong Pipeline: A robust pipeline of CAR-T therapies targeting multiple cancers.
  • Strategic Partnerships: Collaborations with industry leaders like Servier and Allogene Therapeutics.
  • Market Potential: Significant growth opportunities in both the therapeutic and agricultural sectors.

Risks

  • Financial Uncertainty: The company is not yet profitable and may require additional funding.
  • Regulatory Hurdles: The approval process for gene-editing therapies is uncertain and time-consuming.
  • Competitive Pressure: Intense competition from other biotech firms.

Conclusion

Cellectis S.A. is at the forefront of gene-editing innovation, with a strong focus on developing allogeneic CAR-T therapies and sustainable agricultural solutions. While the company faces challenges such as regulatory hurdles and financial uncertainty, its proprietary TALEN® technology and strategic partnerships position it well for future growth. As the demand for innovative healthcare and agricultural solutions continues to rise, Cellectis is poised to play a significant role in shaping the future of these industries.